Endocrine & Metabolic Disorders
ICON's endocrine and metabolic trial experience, supported by a global team of experts
A multifaceted risk factor:
Addressing obesity's impact across the disease spectrum
Obesity is a growing health concern worldwide, with at least 2.8 million people dying each year because of the disease. Explore the implications of obesity as a risk factor across the disease spectrum, and how this may impact treatment, drug development and clinical trials for obesity.
ICON survey report:
Trends and challenges in obesity research and clinical trials
Explore the ICON survey of global industry professionals currently engaged in obesity-related clinical research. Respondents were from organisations ranging from small biotechs to large pharmaceutical companies, as well as academic organisations. The survey was designed to measure industry opinions on trends and challenges for the sector.
Webinar: Addressing the challenges of Type 2 Diabetes global clinical trials via high quality lab solutions
Join ICON’s expert Dr. Andrew Roche, PhD as he speaks about overcoming challenges when developing Diabetes trials. Addressing these challenges via use of high quality tools is critical to successful completion of a clinical trial.
Webinar: Digital solutions to alleviate NASH clinical trial challenges
Find out more about the ability for digital technologies including magnetic resonance imaging (MRI), magnetic resonance elastography (MRE) and whole slide imaging (WSI) to address NASH clinical trial challenges.
Endocrine and metabolic disorders blogs and media contributions
-
Blog: Obesity-related liver conditions: Understanding treatment options
Explore obesity’s role in liver disease progression and the value of different treatment options providing renewed hope to patients.
-
Blog: Designing clinical trials for a complex disease: Pediatric obesity
Pediatric obesity is a complex disease with multiple factors for sponsors to consider when designing and executing treatment trials.
-
Blog: A dynamic market: Trends transforming the future of obesity drug development
Learn about the future of obesity drug development and explore how GLP-1 drugs and multi-indication therapies are transforming treatment.
-
Media article: Obesity trial surge puts the focus back on decentralisation
Explore the evolving obesity clinical trials landscape and the role of decentralisation and new technologies in this recent CTA article.
-
Media article: Liver disease, obesity and the value of treatment
The link between obesity and metabolic-dysfunction associated steatotic liver disease (MASLD), and touches on recent advancements in effective treatments for obesity.
-
Media article: Pharma’s obsession with obesity on rise
ICON experts, Jack Martin and Simon Bruce share insights with BioSpectrum Asia on emerging trends in obesity treatment and the future implications for pharma.
-
Media article: Paediatric clinical trials for obesity treatment
In this article, ICON experts Alan Baldridge and Heather Peterson discuss the prevalence of paediatric obesity and assess clinical trials of its treatments.
-
Media article: Taking Stock of Obesity Drug Development: Trends and challenges facing today’s researchers
In this article, ICON’s Jack Martin discusses the direction obesity drug research is heading, and the challenges faced by researchers.
Endocrine & Metabolic Disorders services
ICON is an experienced partner who can assist sponsors in navigating the many challenges of endocrine & metabolic disorders drug development. ICON can help sponsors optimise the clinical trial lifecycle from patient enrolment to payer reimbursement with its customisable solutions and proven strategies. Our highly experienced clinical and therapeutic teams have expertise in conducting trials across a wide range of therapeutic areas including, diabetes, cardiometabolic disorders, gastroenterology, and hepatology.